ARIAD to Host Analyst & Investor Day in New York City

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

ARIAD Pharmaceuticals, Inc. ARIA today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.m. (EDT) in New York City. Paris Panayiotopoulos, president and chief executive officer of ARIAD, will host the event along with other key members of ARIAD senior management. The meeting will focus on ARIAD's completion of its corporate strategic review, as well as provide an update on continued progress in its research and development and commercial programs. Expert medical leaders in the fields of chronic myeloid leukemia and non-small cell lung cancer will be featured speakers and discussants at the meeting.

A live webcast of the Analyst & Investor Day can be accessed by visiting the investor relations section of ARIAD's website at http://www.ariad.com/investor.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is an orphan oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other orphan cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

View source version on businesswire.com: http://www.businesswire.com/news/home/20160608005162/en/